Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of Zimlovisertib in Healthy Subjects
NCT02485769Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) comparing Zimlovisertib with Placebo (2 arms). Primary endpoints: Incidence and severity of treatment emergent adverse events at 50 days, Incidence and Magnitude of Participants with Treatment-emergent hematology clinical abnormalities at 50 days and 9 more. Started Jun 2015; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02485769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485769.